Additional Relevant Details Based on its recent meetings with the U.S. Food and Drug Administration (FDA), Puma Biotechnology now plans to submit its New Drug Application (NDA) for the approval of neratinib for the treatment of extended adjuvant breast cancer that has previously been treated with a trastuzumab-containing regimen in mid-2016.